Quality of Sex Life in Patients with Inflammatory Bowel Disease: The Gastroenterologists' Perspective
No abstract available (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Online Only: Letters to the Editor Source Type: research
Caution When Assessing Immunity to Varicella Through Antibody Testing in Patients with Inflammatory Bowel Disease
No abstract available (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Online Only: Letters to the Editor Source Type: research
Fecal Calprotectin in Pregnancy
No abstract available (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Online Only: Letters to the Editor Source Type: research
Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease
No abstract available (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Online Only: Letters to the Editor Source Type: research
Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study
Conclusions: In both the high- and low-risk cohorts in this study, premedication use was not effective in reducing the rate of acute IFX reactions. Given this, routine premedication use is not recommended without future randomized control trials to demonstrate efficacy. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing
Background: There are substantial global differences in the preference for mercaptopurine (MP) or its prodrug azathioprine (AZA) as first-choice thiopurine to treat inflammatory bowel diseases. Studies comparing both agents are scarce. Our aim was to compare AZA and MP in thiopurine-naive patients with inflammatory bowel disease for the frequency of side effects and efficacy.
Methods: Post hoc analysis of the “Thiopurine response Optimization by Pharmacogenetic testing in Inflammatory bowel disease Clinics” (TOPIC) trial, in which thiopurine-naive patients with inflammatory bowel disease with an indication for a thiop...
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Sarcopenia is a Predictor of Surgical Morbidity in Inflammatory Bowel Disease
Conclusions: In this population, the average age of sarcopenic patients is increased from those who do not meet criteria. Among patients younger than 40 years, sarcopenia affects surgical outcomes. Assessment of sarcopenia can be used to improve preoperative management and describe risks before surgery in patients with IBD. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement
Conclusions: Patients who had the setons placed before treatment with biologics used fewer health care resources and incurred lower health care costs compared with those who did not have the procedure. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab
Conclusion: This is the first study to show that optimization of IFX is more frequent and faster in obese and overweight patients with CD and occurs within 12 months after beginning IFX, suggesting that an induction regimen with higher doses of IFX and a tight control of IFX concentrations may be needed in these patients. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection
Background: Risk of venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD) is well established; however, there is paucity of data on the potential added risk of VTE in patients with IBD with Clostridium difficile infection (CDI). We sought to study the difference in VTE rates in hospitalized patients with IBD with CDI compared to those without CDI.
Methods: We queried Nationwide Inpatient Sample from year 2011 to identify patients ≥18 years of age with a discharge diagnosis of IBD (i.e., Crohn's disease and ulcerative colitis) based on ICD-9-CM codes 555.xx and 556.xx, respectively. Patients were...
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study
Conclusions: In this real-life study, up to one-third of patients with Crohn's disease did not start preventive therapy after intestinal resection, and almost half of them were not endoscopically monitored as recommended. In this setting, 30% of patients developed clinical POR within the first 5 years after surgery, thus indicating that there is room for improvement. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions
Conclusions: Both early and late hospital readmissions are common in patients with IBD. Because frequent readmissions are indicators of poor quality of care, future prospective studies using larger cohorts of patients are needed to identify modifiable factors in patient care before discharge to improve quality of care, prevent readmissions, and consequently reduce health care costs. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort
This study examines factors that may influence time to diagnosis and disease outcomes in a U.S. patient cohort.
Methods: We retrospectively collected data on patient characteristics, time to diagnosis, disease phenotype, and complications in 177 patients with inflammatory bowel disease (110 CD and 67 UC) diagnosed at our institution from 2008 to 2015. Factors potentially affecting time to diagnosis were analyzed. Association between disease complications (perianal disease, intestinal strictures, surgery, fistula, abscess, and perforation) and time to diagnosis was tested by multivariable analysis.
Results: The median tim...
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease
Background: Interleukin (IL)-9 drives gut inflammation, but its role in Crohn's disease (CD) is unclear. We aimed to analyze correlations between serum IL-9 levels and disease severity and to evaluate their predictive value in relation to the clinical efficacy of infliximab (IFX) in patients with CD.
Methods: Between January 2013 and December 2015, 100 consecutive patients with active CD and 50 age- and sex-matched control individuals were recruited from a tertiary center. Their serum IL-9 levels were measured using an enzyme-linked immunosorbent assay. Correlations between the serum IL-9 levels and disease severity were ...
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort
Conclusions: In children with inflammatory bowel disease, TiPN is common but mild and generally reversible. Cumulative dose seems to be the most relevant risk factor, whereas polymorphisms in genes involved in neuronal inflammation may be protective. (Source: Inflammatory Bowel Diseases)
Source: Inflammatory Bowel Diseases - October 1, 2017 Category: Gastroenterology Tags: Original Clinical Articles Source Type: research
